anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention refers to biotechnology, immunology and virology. There is created a pharmaceutical agent for inducing specific immunity to the virus of severe acute respiratory syndrome SARS-CoV-2, containing component 1 representing an agent in form of an expression vector based on the recombinant human adenovirus genotype of 26 serotype in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an inbuilt expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and containing component 2, which is an agent in the form of an expression vector based on the genome of recombinant human adenovirus strain of 5 serotype in which E1 and E3 regions are deleted, with an inbuilt expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. Also created is a pharmaceutical agent for inducing specific immunity to the virus of severe acute respiratory syndrome SARS-CoV-2, containing component 1, which is an agent in form of an expression vector based on the genome of the recombinant human adenovirus strain of 26 serotype, in which the E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an inbuilt expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, as well as containing component 2, which is agent in form of expression vector based on recombinant strain of simian adenovirus 25 serotype genome, in which the E1 and E3 regions are deleted, with an inbuilt expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3. There is also created a pharmaceutical agent for inducing specific immunity to the virus of severe acute respiratory syndrome SARS-CoV-2, containing component 1, representing an agent in the form of an expression vector based on the genome of the recombinant strain of simian adenovirus of 25 serotype, in which the E1 and E3 regions are deleted, with an inbuilt expression cassette selected from SEQ ID NO: 4, SEQ ID NO: 2, SEQ ID NO: 3, as well as containing component 2, which is an agent in form of an expression vector based on genome of human recombinant strain of human adenovirus of 5 serotype, in which E1 and E3 regions are deleted, with an inbuilt expression cassette selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3. Each pharmaceutical agent is in a liquid or lyophilised form, and component 1 and component 2 are in different packages. Each pharmaceutical agent is used to induce specific immunity to the virus of severe acute respiratory syndrome SARS-CoV-2, wherein components 1 and 2 are used in an effective amount sequentially with an interval of not less than 1 week. The invention provides development of reactions of humoral and cellular immune response against SARS-CoV-2, thus providing increased level of immune response against virus SARS-CoV-2.
BACKGROUND: Preoperative prism adaptation (PPA) simulates postoperative status and possibly can predict postoperative undercorrection before surgery in esotropia. The present study aimed to assess the effect of 4-week PPA in preventing postoperative residual esotropia.
METHODS: Seventy-five (75) esotropes who had undergone surgery at a single strabismus center were retrospectively enrolled. They included 25 basic, 31 acute comitant, 10 partially accommodative, and 9 recurrent esotropia patients. The preoperative deviation angle, which had been determined using the alternating prism and cover test, was fully corrected with press-on prisms 4 weeks before surgery. If there was an increase of 5 PD or more of esodeviation, the prisms were changed accordingly at 2 weeks. The deviation angle measured at 4 weeks was determined as the surgical target angle. Patients were then divided into increase (≥ 5 PD increase of angle during 4-week PPA) and non-increase groups. Success was defined as either esodeviation of 8 PD or under or exodeviation of 5 PD or under at distance at postoperative 6 months.
RESULTS: The increase group included 44 patients (58.7%). The mean deviation angle before PPA was 27.4 PD, and after the 4-week PPA, there was an average increase of 9.4 PD. The success rate was 90.9% in the increase group and 96.8% in the non-increase group (p = 0.316). There were no intergroup differences in preoperative clinical characteristics, esotropia types, postoperative deviation angle or postoperative near stereopsis (p > 0.05).
CONCLUSIONS: The results of this study indicated a beneficial effect of 4-week PPA in esotropia of various types, specifically by uncovering the hidden esodeviation in the increase group and simulating the postoperative alignment in both the increase and the non-increase groups.
BACKGROUND: Major depressive disorder (MDD) and frailty impose substantial health and economic burdens. MDD is recognized as a significant risk factor for frailty, but the genetic associations between these conditions remain unclear. This study investigates the genetic correlation, shared pleiotropic loci, causal relationships, and comorbid genes between MDD and frailty.
METHODS: The genetic correlation between MDD and frailty was assessed using linkage disequilibrium score regression (LDSC) based on data from genome-wide association studies (GWAS). A detailed analysis was performed to identify shared pleiotropic loci and causal relationships through cross-phenotype association tests and Mendelian randomization. Additionally, tissue enrichment analysis was conducted using stratified LDSC, gene-based associations with both conditions were assessed using Multimarker Analysis of Genomic Annotation (MAGMA), and pathway analysis of comorbid genes was performed using the g: GOSt tool.
RESULTS: Our findings revealed a significant positive genetic correlation between MDD and frailty (rg = 0.65, P = 1.49E-219). We identified 57 shared risk SNPs between the two conditions, including 6 novel SNPs. Mendelian randomization analyses indicated robust causal effects of MDD on frailty and vice versa. Furthermore, we observed tissue-specific heritability enrichment in 9 brain tissues. By combining MAGMA and CPASSOC analyses, we identified 10 comorbid genes associated with both MDD and frailty, primarily involved in synapse formation, modulation, plasticity, and desaturase activity.
CONCLUSION: This study provides strong evidence for a shared genetic basis between MDD and frailty. The identification of comorbid genes offers new insights into the mechanisms underlying the relationship between these conditions.
The antineuritic vitamin is extracted from materials containing it, such as rice-polishings, yeast, oat hulls, malt coombs, seeds and seed integuments, by treating an aqueous extract with an ion-exchanging material and then treating the ion-exchanging material with a neutral salt or dilute acid solution to obtain a salt of the vitamin.  As ion - exchanging material, there may be used zeolites, especially wet-process zeolites, glauconite, fuller's earth and other earthy materials having the adsorbent and ion-exchanging powers of fuller's earth; or a zeolite which has been treated with an acid to replace the base metal by hydrogen. The initial extract is preferably slightly acid, and, when made, is neutralized and filtered, the filtrate containing the vitamin; when the raw material is yeast, the extract may be purified by treatment with lead acetate before treatment with the ion-exchange material.  The vitamin may be extracted from the ionexchange material by treatment with dilute nitric acid or by solutions of salts such as ammonium or barium nitrate or sodium chloride, potassium chloride or calcium nitrate. The yield may be increased by treatment first with ammonium nitrate and then with barium nitrate solutions.  The vitamin is advantageously recovered as the hydrochloride, in which case this compound may be precipitated by means of alcohol.  The vitamin solution after removal from the ion-exchange material may be purified by conversion into the silver salt or by precipitation with a silico-tungstate or phosphotungstate.  In an example, ricepolishings are extracted with slightly acidified 15 per cent alcohol (pH 4,5), the extract being neutralized with barium oxide, the precipitate is removed, the solution again brought to pH 4,5 and percolated through a zeolite which has been previously treated with sulphuric acetic or other dilute acid at pH 4,5 and 75-80 DEG  C.; the solution thus obtained may be neutralized with caustic soda, the precipitated impurities removed, and silver nitrate added, the precipitate being treated with nitric acid (pH 3) and then ammonia (to pH 4,5); then a little silver nitrate and ammonia are added successively and the precipitated silver compound of the vitamin is treated with hydrochloric acid to remove the silver.  Further purification may be effected by precipitation with silicotungstic acid in several stages, the wet precipitates being decomposed with baryta water whereby barium silicotungstate forms and the vitamin dissolves; it may be converted to the hydrochloride, evaporated to dryness, and, if desired, further purified by dissolving in water and adding absolute alcohol which may contain a little petroleum ether.
<P>PROBLEM TO BE SOLVED: To provide dissolving granules in which elution rate of a material (active ingredient) contained can be set and to provide a method for producing the dissolving granules.  <P>SOLUTION: In the dissolving granules 1, a cosmetic material 11 which is an active ingredient and a binder material 12 are kept in uniformly mixed and hardened state on the surface of nuclear particles which become nucleus of the shape and elution rate of the cosmetic material 11 to a liquid (e.g. hot water) is determined by weight ratio of each component. Although it is difficult to granulate the cosmetic material 11 alone, granulation is carried out by using the nuclear particles 10 and the binder material and the granulated material is sintered at a low temperature to provide granules having adequate hardness. The elution rate of the cosmetic material 11 is delayed by forming the cosmetic material 11 as granules and the granules enables long-term continuous use of the cosmetic material 11 and can suppress putrefaction and deterioration of the active ingredient contained.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The invention discloses an externally applied patch, which is used for treating gastrointestinal dysfunction and is specially offered to adults. The externally applied patch comprises a medical non-woven fabric layer, a drug layer and a protective layer from inside to outside. The drug layer contains externally applied powder and glycerin. The medical non-woven fabric is uniformly smeared with the externally applied powder and glycerin and then the medical non-woven fabric is inserted into the protective layer so that the externally applied patch is prepared. The externally applied patch comprises, by weight, 10-15 parts of radix ophiopogonis, 10-15 parts of anemarrhena, 8-12 parts of hedyotis diffusa, 8-12 parts of guava leaf, 5-10 parts of banksia rose, 5-10 parts of wrinkled giant hyssop, 3-7 parts of ginseng fruit, 3-7 parts of cassia bark and 2-5 parts of dried orange peel. The externally applied patch has functions of easing pain, stopping diarrhea and stopping emesis by being applied to belly, stomach or intestines so that effects of harmonizing intestine-stomach, protecting liver and invigorating spleen, calming nerves and improving sleep quality are obtained.
· What we do not know: Treatment of hydrosalpinx and IVF Several studies in the literature have suggested that the treatment of hydrosalpinx pre-IVF would improve the pregnancy rate to a level similar to tubal disease patients without hydrosalpinx. The treatment modalities explored were salpingectomy, salpingostomy, tubal occlusion and ultrasound-guided aspiration either one month before or at the time of egg collection. All studies reported to date have been retrospective and with poor control design. A prospective randomised controlled trial is needed. All modalities have been associated with a similar improvement in pregnancy rate, but the least invasive modality is ultrasound-guided aspiration at the time of oocyte collection. We propose to conduct a prospective randomised controlled trial to evaluate the effect of ultrasound-guided aspiration (versus no aspiration) of hydrosalpinx at the time of egg collection on the pregnancy rate in IVF.
Participants in the control received no intervention. They completed the questionnaires at the end of weeks 1, 2 and 3, and also completed the surveys at baseline and intervention end.
The present invention discloses a medicine for treating gout, which is proportionally prepared from phellodendron bark, largeleaf gentian root and corydalis tuber. The medicine can be prepared into any general dose form. The medicine of the present invention has the efficiency of removing heat, removing wind, removing dampness, promoting blood circulation to remove meridian obstruction and relieving pain. The medicine has the functions of resisting inflammation, relieving pain, inducing diuresis and activating blood circulation to dissipate blood stasis. The medicine of the present invention is used for treating swelling and thermalgia of the joints, heat pain which are accompanied with heat generation, sweating without excretion, thirst liking drinking, vexation with uneasiness and yellow urine. The medicine of the present invention is suitable for gout patients having the symptoms.
Participants allocated to the intervention condition will receive the nurse-led 5As model intervention at baseline, 1- and 3-month boosters, and 6- and 12-month follow-ups. The current model includes risk assessments and stratification, general health education booklet, consultations and active referrals based on personal risk stratification at baseline and 3-month booster, with additional booster session at 1-month, and follow-up sessions at 6- and 12-month from baseline. For participants with high risk of any target health conditions at baseline and 3-month booster, medical referral and service utilization (e.g., GPs/network doctors/specialist consultation at health centres/hospitals/clinics, screening, therapies, corresponding District Health Centre schemes, etc.) will be arranged at the visits. Such medical resource utilization among participants will be encouraged and motivated at 1-month booster session.
Obesity is closely associated with non-alcoholic fatty liver disease (NAFLD), characterized by hepatic fat accumulation and hepatocyte injury. Preclinical studies have shown exacerbated weight gain associated with an obesogenic gluten-containing diet. However, whether gluten affects obesity-induced hepatic lipid accumulation still remains unclear. We hypothesized that gluten intake could affect fatty liver development in high-fat diet (HFD)-induced obese mice. Thus, we aimed to investigate the impact of gluten intake on NAFLD in HFD-induced obese mice. Male apolipoprotein E-deficient (Apoe-/-) mice were fed with a HFD containing (GD) or not (GFD) vital wheat gluten (4.5%) for 10 weeks. Blood and liver were collected for further analysis. We found that gluten exacerbated weight gain, hepatic fat deposition, and hyperglycemia without affecting the serum lipid profile. Livers of the GD group showed a larger area of fibrosis, associated with the expression of collagen and MMP9, and higher expression of apoptosis-related factors, p53, p21, and caspase-3. The expression of lipogenic factors, such as PPARγ and Acc1, was more elevated and factors related to beta-oxidation, such as PPARα and Cpt1, were lower in the GD group compared to the GFD. Further, gluten intake induced a more significant expression of Cd36, suggesting higher uptake of free fatty acids. Finally, we found lower protein expression of PGC1α followed by lower activation of AMPK. Our data show that gluten-containing high-fat diet exacerbated NAFLD by affecting lipogenesis and fatty acid oxidation in obese Apoe-/- mice through a mechanism involving lower activation of AMPK.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to development of agents of vegetable origin as a hepatoprotective drug. Invention proposes viburnum crowns spirituous extract as a hepatoprotector. The proposed agent inhibits free-radical reactions and decreases formation of toxic products of lipid peroxidation processes, stabilizes lysosomal membranes and inhibits release of hepatocyte membranotropic hydrolases to cytoplasm, normalizes liver function that is characterized by synthesis of phospholipids from triacylglycerol and shows others effects. EFFECT: enhanced effectiveness of agent, valuable medicinal and biochemical properties. 1 cl, 5 tbl
The impact of different forms of dietary fiber (total, insoluble or soluble) derived from the same source on health remains incompletely understood. In this study, the effects of total, insoluble, and soluble dietary fiber extracted from highland barley (HDF, HIDF, and HSDF) on combating obesity were evaluated and compared. A high-fat diet (HFD) was used to induce obesity in a murine model, followed by gavage administration of HDF, HIDF, or HSDF, and a comprehensive multi-omics approach was utilized to assess and compare the effects of these dietary fibers on obesity-related parameters. The results showed that all three dietary fibers significantly reduced body weight, modified blood lipid profiles, and ameliorated tissue damage in HFD-fed mice. Additionally, 16S rRNA sequencing analysis of mice feces showed that three types of dietary fiber exerted varying degrees of impact on the composition and abundance of gut microbiota while simultaneously promoting the biosynthesis of short-chain fatty acids. Specifically, HDF supplementation remarkably enhanced the abundance of Coprococcus, while HIDF and HSDF supplementation elevated the levels of Akkermansia and Allobaculum, respectively. Transcriptomic and proteomic results suggested the PPAR signaling pathway as a central regulatory mechanism influenced by these fibers. HDF and HIDF were particularly effective in modulating biological processes related to triglyceride and fatty acid metabolism, identifying Abcc3 and Dapk1 as potential targets. Conversely, HSDF primarily affected processes related to membrane lipids, ceramides, and phospholipids metabolism, with Pck1 identified as a potential target. Collectively, HDF, HIDF, and HSDF demonstrated distinct mechanisms in exerting exceptional anti-obesity properties. These insights may inform the development of personalized dietary interventions for obesity.
The invention provides a method for removing lead from aloe. The method comprises the steps of squeezing the aloe raw material to obtain juice, filtering the juice and sterilizing the filtrate to obtain aloe normal juice, subjecting the aloe normal juice to ion-exchange adsorption for removing lead, concentrating the obtained product, and subjecting the concentrated product to normal process to obtain dried aloe powder. The method provided in the invention is easy to operate, the lead removing effect is good, and the dried aloe powder in which lead is removed has the lead content of less than 0.3 mg/kg. Employed resin can be recycled so that the environmental pollution is decreased, and the production cost is reduced. Ion exchange resin has specificity, the contact time is short, polysaccarides and functional components are not lost, and diatomite has effective adsorption function, therefore, turbid substances in the aloe slurry is effectively removed, and the obtained aloe product is pure. The method for removing lead from aloe has very good economic and social benefits.
We are studying the impact of sexual dysfunction following radical prostatectomy on patient and partners' experiences of intimacy. Research with men in post-radical prostatectomy recovery indicates 25%-75% experience sexual dysfunction. Many patients experience anxiety and distress related to sexual difficulties. These experiences may progress and result in long-term problems in the relationship between patients and their partners. Despite apparent levels of effectiveness, up to half of the patients who turn to sexually assistive aids after surgical removal of the prostate discontinue use of the aids within one year. Additionally, difficulties in communicating about sexual impairments can significantly interfere with the couples' ability to achieve successful adaptation. We are interested in studying patient and partner experiences with sexual dysfunction in order to understand its effects on sexual and non-sexual intimacy.

Participation in this study will involve completing 6 confidential face-to-face interviews on three separate occasions (3-6 months, 12-15 months, and 21-24 months post-surgery). On each occasion, participants will be required to take part in a "couple's" interview with his/her partner, as well as an individual interview. The interviews will provide participants with the opportunity to discuss the impact of sexual dysfunction on mood, thoughts, and communication with their partners. Demographic information will be collected at the initial interview. As well, at each of the 3 time points, participants will also be asked to complete a questionnaire package containing 6 psychological questionnaires. All questionnaires and interview material will be kept strictly confidential.
The present invention relates to a skin cosmetic composition containing an Acanthopanax seoulensis Nakai embryo stem cell extract. The Acanthopanax seoulensis Nakai embryo stem cell extract of the present invention is generated from an endangered plant which is difficult to be obtained in a natural state. The Acanthopanax seoulensis Nakai embryo stem cell extract can be useful as a skin cosmetic composition by having a whitening activity, an antioxidant function, and cell safety. The cosmetic composition of the present invention contains an Acanthopanax seoulensis Nakai embryo stem cell extract, blocs the generation of melanin by controlling the enzyme activity of tyrosinase, and has a whitening activity. Moreover, cytotoxicity is very low, so the present invention is useful as a safe cosmetic composition compared to albutin which is a material of a whitening cosmetic product. The Acanthopanax seoulensis Nakai embryo stem cell extract is the result of the invention which cannot be obtained in a natural state, and is a useful cosmetic composition for maintaining skin health and clearness.
Metabolic reprogramming underlies the etiology and pathophysiology of respiratory diseases such as asthma, idiopathic pulmonary fibrosis (IPF), and chronic obstructive pulmonary disease (COPD). The dysregulated cellular activities driving airway inflammation and remodelling in these diseases have reportedly been linked to aberrant shifts in energy-producing metabolic pathways: glycolysis and oxidative phosphorylation (OXPHOS). The rewiring of glycolysis and OXPHOS accompanying the therapeutic effects of many clinical compounds and natural products in asthma, IPF, and COPD, supports targeting metabolism as a therapeutic approach for respiratory diseases. Correspondingly, inhibiting glycolysis has largely attested effective against experimental asthma, IPF, and COPD. However, modulating OXPHOS and its supporting catabolic pathways like mitochondrial pyruvate catabolism, fatty acid β-oxidation (FAO), and glutaminolysis for these respiratory diseases remain inconclusive. An emerging repertoire of metabolic enzymes are also interconnected to these canonical metabolic pathways that similarly possess therapeutic potential for respiratory diseases. Taken together, this review highlights the urgent demand for future studies to ascertain the role of OXPHOS in different respiratory diseases, under different stimulatory conditions, and in different cell types. While this review provides strong experimental evidence in support of the inhibition of glycolysis for asthma, IPF, and COPD, further verification by clinical trials is definitely required.